Insider Selling: Neuronetics, Inc. (NASDAQ:STIM) CFO Sells 17,307 Shares of Stock

Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) CFO Stephen Furlong sold 17,307 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $4.11, for a total value of $71,131.77. Following the completion of the transaction, the chief financial officer now owns 454,420 shares in the company, valued at approximately $1,867,666.20. This trade represents a 3.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Stephen Furlong also recently made the following trade(s):

• On Wednesday, February 12th, Stephen Furlong sold 10,845 shares of Neuronetics stock. The stock was sold at an average price of $3.83, for a total value of $41,536.35.
• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The shares were sold at an average price of $3.28, for a total transaction of $48,662.08.

Neuronetics Price Performance

STIM stock traded up $0.23 during midday trading on Thursday, hitting $4.69. The company's stock had a trading volume of 389,065 shares, compared to its average volume of 1,662,066. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. Neuronetics, Inc. has a 12 month low of $0.52 and a 12 month high of $5.07. The company has a 50 day moving average of $2.41 and a two-hundred day moving average of $1.47. The firm has a market capitalization of $142.18 million, a price-to-earnings ratio of -3.82 and a beta of 2.17.

Hedge Funds Weigh In On Neuronetics

Several institutional investors have recently bought and sold shares of the business. HighTower Advisors LLC grew its stake in Neuronetics by 55.5% in the third quarter. HighTower Advisors LLC now owns 245,982 shares of the company's stock worth $187,000 after purchasing an additional 87,816 shares in the last quarter. GSA Capital Partners LLP grew its position in shares of Neuronetics by 64.5% during the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company's stock worth $60,000 after buying an additional 30,837 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Neuronetics in the third quarter worth about $53,000. Balyasny Asset Management L.P. lifted its position in shares of Neuronetics by 29.5% in the 4th quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company's stock worth $2,386,000 after purchasing an additional 337,539 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Neuronetics by 10,954.1% during the fourth quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company's stock worth $88,000 after buying an additional 54,442 shares during the period. Institutional investors own 53.59% of the company's stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.